Cantor Fitzgerald Expects Lower Earnings for GH Research

GH Research PLC (NASDAQ:GHRS) – Equities researchers at Cantor Fitzgerald reduced their FY2025 EPS estimates for GH Research in a research report issued on Monday, May 12th. Cantor Fitzgerald analyst C. Duncan now expects that the company will post earnings of ($0.84) per share for the year, down from their prior forecast of ($0.79). Cantor Fitzgerald currently has a “Overweight” rating and a $14.00 price target on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

GHRS has been the topic of a number of other reports. Royal Bank of Canada began coverage on shares of GH Research in a report on Friday, March 7th. They set an “outperform” rating and a $31.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Friday, May 9th. Stifel Nicolaus lifted their target price on GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Finally, Guggenheim lowered their price target on shares of GH Research from $32.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, GH Research presently has an average rating of “Buy” and a consensus target price of $30.43.

GH Research Price Performance

NASDAQ GHRS opened at $10.06 on Wednesday. The firm has a market cap of $523.40 million, a P/E ratio of -12.73 and a beta of 0.86. The stock’s 50-day moving average is $10.29 and its 200-day moving average is $9.89. GH Research has a one year low of $6.00 and a one year high of $20.50.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.42.

Institutional Trading of GH Research

A number of institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new position in GH Research in the fourth quarter valued at about $44,000. Palumbo Wealth Management LLC acquired a new stake in GH Research during the first quarter worth approximately $142,000. XTX Topco Ltd acquired a new stake in GH Research in the first quarter worth $169,000. Two Sigma Investments LP acquired a new position in GH Research during the 4th quarter worth approximately $117,000. Finally, Millennium Management LLC bought a new position in shares of GH Research in the 4th quarter worth $145,000. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).